Moderna Q1 2026: revenue $389 million, GAAP loss $1.3 billion after $878 million settlement charge

Moderna reported first-quarter 2026 revenue of $389 million, up from $108 million a year earlier, with about 80% from international markets. The GAAP net loss widened to $1.34 billion, or $(3.40) per share, because of a non-recurring litigation charge in cost of sales. Excluding that charge, management kept up to 10% revenue growth for 2026 and lower operating expenses, and R&D and SG&A both fell sharply year on year.

• Q1 2026 revenue: $389 million (Q1 2025: $108 million); US $78 million, international $311 million
• Net product sales: $352 million (Q1 2025: $86 million)
• GAAP net loss: $(1,343) million, EPS $(3.40), including the $878 million settlement charge
• R&D $649 million (down 24%), SG&A $173 million (down 18%)
• Cash and investments $7.5 billion at March 31, 2026; year-end guidance $4.5 to $5.0 billion

SEC filing 8-K · accession 0001682852-26-000057 · sec.gov ↗